Follow the User Guide to start building your site.
-
-
Pivotal trial (safety data)
-
It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.
This website is for non-promotional purposes and is intended for providing
safety information for US healthcare professionals (HCP) only
Please confirm that you are an HCP from the US
For HCPs outside the US: thank you for your interest in the safety website for siponimod in multiple sclerosis. This website is intended for HCPs in the US only. A global website for HCPs outside the US will be launched in Q1 2021. In the meantime please visit www.novartis.com
For non-HCPs/patients: this safety website is available for US HCPs only.
The Pregnancy outcome Intensive Monitoring (PRIM) program is based on enhanced pharmacovigilance of the Novartis spontaneous reporting system. PRIM is an adverse event outcomes intensive monitoring program to collect information (targeted follow-up checklists) about pregnancy in patients exposed to siponimod immediately before or during pregnancy and infant outcomes 12 months after delivery.